Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million investment creating 45 new full-time jobs in the area.

Piramal Pharma Solutions (PPS), the global contract manufacturing division of Piramal Pharma Ltd, is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky. Piramal's global Contract Development and Manufacturing ...

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new lab, and state‐of‐the‐art machinery.

Piramal Pharma’s stock price rose 2% in the opening trading on September 30 after the business received an Establishment Inspection Report (EIR) for its production facility in Ahmedabad, India. The USFDA examined the plant in July 2024 and issued a No Action Indicated (NAI) classification based on Zero Form – 483 observations.

The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising demand, said the company.

Piramal Pharma Solutions invests $80 million in Lexington facility expansion to meet growing demand in injectables market.

Mumbai: Piramal Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its manufacturing facility in Ahmedabad, India. This follows